Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL RegistryAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL RegistryAnthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.
Blood Advances|April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sitesAnthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
British Journal of Haematology|November 19, 2016
Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centresAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
Blood Advances|March 14, 2025
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX studyBei Hu, Patrick M Reagan, Laurie H Sehn, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL RegistryAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL RegistryAnthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.
Blood Advances|April 10, 2020
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sitesAnthony Mato, Chadi Nabhan, Nicole Lamanna, et al.
British Journal of Haematology|November 19, 2016
Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centresAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Leukemia & Lymphoma|November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryNancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
Blood Advances|March 14, 2025
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX studyBei Hu, Patrick M Reagan, Laurie H Sehn, et al.
Pageof 8